News

GEMINI genes

The Beroukhim laboratory performed a systematic exploration of potential therapeutic vulnerabilities deriving from loss of heterozygosity in cancer. Nature Communications, May 2020. Caitlin Nichols, who led the study, gave a great presentation on it as a Harvard Horizons Fellow.

Effects of CAS9 expression on TP53

A study led by current and former Beroukhim lab members, in collaboration with the Golub lab, found that CAS9 expression alone activates the p53 pathway and spurs cell line evolution. These have implications for experiments making use of CAS9. Nature Genetics, May 2020.

Molecular effects of ancestry on cancer

The Beroukhim lab led a TCGA-based effort to evaluate the molecular differences between ancestries across 33 cancer types–the largest and most comprehensive such analysis in diseased or non-diseased tissue, with implications for both. Cancer Cell, May 2020.

Hypermutation in gliomas

The Beroukhim, Bandopadhayay, Bielle, and Ligon labs published a paper describing the evolutionary processes that lead to hypermutation in gliomas, and their therapeutic implications. Nature, April 2020.

PCAWG papers are published

A suite of papers evaluating whole genome sequencing data across ~2700 cancers was published today. This was an international collaborative effort; the Beroukhim lab helped lead two of these papers. Patterns of somatic structural variation in human cancer genomes, Nature, February 2020, and Analyses of non-coding somatic drivers in 2,658 cancer whole genomes, Nature, February 2020.

Uri Ben-David establishes his own lab

Former postdoc Uri Ben-David has now established an independent laboratory in the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University. He is focused on studying the consequences of aneuploidy.

A comprehensive study of cell line evolution

The Beroukhim and Golub laboratories published a paper indicating how extensively cell lines can evolve over time and diverge across laboratories.  The paper was featured on the journal’s cover.  Nature, August 2018.

Linda Bi establishes her own lab

Former postdoc Linda Bi has now established an independent laboratory in the Department of Neurosurgery at Brigham and Women’s Hospital, as an Assistant Professor at Harvard Medical School.  She is focused on tumors of the skull base.

SvABA: an assembly-based rearrangement detection tool

The Beroukhim laboratory published a new tool to detect rearrangements in DNA sequencing data, with improved accuracy over prior methods. Genome Research, April 2018.

Lab publishes study of evolution in PDX models

The Beroukhim and Golub laboratories published a paper demonstrating substantial evolution of human tumor xenografts in mice.  The paper received coverage in Nature News, Ars Technica, and The Scientist.  Nature Genetics, October 2017.

Beroukhim Lab receives St. Baldrick’s Foundation grant

A new research grant award from St. Baldrick’s Foundation is supporting the Beroukhim Lab’s research in intratumoral heterogeneity of resistance drivers in diffuse intrinsic pontine gliomas (DIPG) to help determine how DIPG becomes resistant to treatments.

Lab publishes largest study to date of genetic abnormalities in pediatric brain tumors

The Beroukhim Lab recently published the largest clinical study to date of genetic abnormalities in pediatric brain tumors, demonstrating that testing pediatric brain tumor tissue for genetic abnormalities is clinically feasible and can guide patients’ treatment. Neuro-Oncology, May 2017.

Comments are closed